Literature DB >> 22441356

Expression of interleukin-4 and interleukin-13 and their receptors in colorectal cancer.

Andrea Formentini1, Philipp Braun, Harald Fricke, Karl-Heinrich Link, Doris Henne-Bruns, Marko Kornmann.   

Abstract

PURPOSE: Interleukin-4 (IL-4) and interleukin-13 (IL-13) are anti-inflammatory and immunomodulatory cytokines which can influence cancer-directed immunosurveillance. Nothing is presently known about expression of these cytokines and their receptors (IL-4R and IL-13R) in colorectal cancer. The aim of this study was to characterize their expression in primary colorectal cancer specimens and to evaluate possible functions for this disease.
METHODS: Expression of IL-4, IL-13, IL-4R, and IL-13R protein was characterized by immunohistochemistry in 359 patients with Union for International Cancer Control stage I-III colorectal cancer and evaluated by uni- and multivariate analysis for their prognostic relevance.
RESULTS: All four proteins were expressed in colorectal cancer specimens. In the cancer cells, high IL-4, IL-13, IL-4R, and IL-13R immunoreactivity were present in 33 % (118/359), 50 % (181/359), 36 % (129/359), and 42 % (152/359), respectively. Patients with high expression of IL-4, IL-4R, and IL-13R had a lower frequency of lymph node metastases. Expression of IL-13 did not influence the frequency of lymph node metastases. However, high IL-13-immunoreactivity was associated with a better overall survival (p = 0.041). Expression of IL-4, IL-4R, or IL-13R did not influence survival. Multivariate analysis revealed that besides pT classification and tumor recurrence, IL-13 expression was an independent prognostic factor for overall survival.
CONCLUSIONS: Expression of IL-4, IL-4R, and IL-13R are involved in the process of local metastases in colorectal cancer, while IL-13 expression has an impact on survival. These interleukins and their receptors may become attractive targets for the treatment of colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22441356     DOI: 10.1007/s00384-012-1456-0

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  28 in total

1.  IL-13 receptor-alpha2: a novel target for cancer therapy.

Authors:  Bharat H Joshi; Raj K Puri
Journal:  Immunotherapy       Date:  2009-05       Impact factor: 4.196

Review 2.  Cytokines, inflammation and colon cancer.

Authors:  Lidija Klampfer
Journal:  Curr Cancer Drug Targets       Date:  2011-05       Impact factor: 3.428

3.  Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain.

Authors:  D Caput; P Laurent; M Kaghad; J M Lelias; S Lefort; N Vita; P Ferrara
Journal:  J Biol Chem       Date:  1996-07-12       Impact factor: 5.157

4.  Thymidylate synthase expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker?

Authors:  Andrea Formentini; Sylvia Sander; Stephanie Denzer; Joern Straeter; Doris Henne-Bruns; Marko Kornmann
Journal:  Int J Colorectal Dis       Date:  2006-03-15       Impact factor: 2.571

5.  The cytokine microenvironment of human colon carcinoma. Lymphocyte expression of tumor necrosis factor-alpha and interleukin-4 predicts improved survival.

Authors:  R J Barth; B J Camp; T A Martuscello; B J Dain; V A Memoli
Journal:  Cancer       Date:  1996-09-15       Impact factor: 6.860

6.  Immunohistochemical expression of interleukin-4, -6, -8, and -12 in inflammatory cells in surrounding invasive front of oral squamous cell carcinoma.

Authors:  Marcos Vinícius Macedo de Oliveira; Carlos Alberto de Carvalho Fraga; Ricardo Santiago Gomez; Alfredo Maurício Batista D Paula
Journal:  Head Neck       Date:  2009-11       Impact factor: 3.147

7.  Tumor cells secreting IL-13 but not IL-13Ralpha2 fusion protein have reduced tumorigenicity in vivo.

Authors:  Hak-Ling Ma; Matthew J Whitters; Bruce A Jacobson; Deborah D Donaldson; Mary Collins; Kyriaki Dunussi-Joannopoulos
Journal:  Int Immunol       Date:  2004-06-07       Impact factor: 4.823

8.  Experimental gene therapy of cancer using tumor cells engineered to secrete interleukin-13.

Authors:  S Lebel-Binay; B Laguerre; F Quintin-Colonna; H Conjeaud; M Magazin; B Miloux; F Pecceu; D Caput; P Ferrara; D Fradelizi
Journal:  Eur J Immunol       Date:  1995-08       Impact factor: 5.532

9.  Obligatory role for interleukin-13 in obstructive lesion development in airway allografts.

Authors:  Vibha N Lama; Hiroaki Harada; Linda N Badri; Andrew Flint; Cory M Hogaboam; Andrew McKenzie; Fernando J Martinez; Galen B Toews; Bethany B Moore; David J Pinsky
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

10.  Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.

Authors:  Masaki Terabe; So Matsui; Jong-Myun Park; Mizuko Mamura; Nancy Noben-Trauth; Debra D Donaldson; Wanjun Chen; Sharon M Wahl; Steven Ledbetter; Bruce Pratt; John J Letterio; William E Paul; Jay A Berzofsky
Journal:  J Exp Med       Date:  2003-12-01       Impact factor: 14.307

View more
  23 in total

1.  Interleukin-4 receptor-targeted liposomal doxorubicin as a model for enhancing cellular uptake and antitumor efficacy in murine colorectal cancer.

Authors:  Chih-Yung Yang; Hong-Wen Liu; Ya-Ching Tsai; Ju-Yu Tseng; Shu-Ching Liang; Chin-Yau Chen; Wei-Nan Lian; Ming-Cheng Wei; Maggie Lu; Ruey-Hwa Lu; Chi-Hung Lin; Jeng-Kai Jiang
Journal:  Cancer Biol Ther       Date:  2015-10-05       Impact factor: 4.742

2.  Deciphering the involvement of iron targets in colorectal cancer: a network biology approach.

Authors:  Abdul Arif Khan; Mohd Tashfeen Ashraf; Fahad M Aldakheel; Ayca Sayi Yazgan; Rana Zaidi
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

Review 3.  Hepatitis-related hepatocellular carcinoma: Insights into cytokine gene polymorphisms.

Authors:  Mahmoud Fathy Dondeti; Eman Anwar El-Maadawy; Roba Mohamed Talaat
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

Review 4.  Cytokine stimulation of epithelial cancer cells: the similar and divergent functions of IL-4 and IL-13.

Authors:  Miranda A Hallett; Katherine T Venmar; Barbara Fingleton
Journal:  Cancer Res       Date:  2012-12-07       Impact factor: 12.701

5.  Evaluation of specific fecal protein biochips for the diagnosis of colorectal cancer.

Authors:  Hui-Peng Wang; Yang-Yun Wang; Jie Pan; Rong Cen; Yuan-Kun Cai
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

6.  Low serum interleukin-13 levels correlate with poorer prognoses for colorectal cancer patients.

Authors:  Susumu Saigusa; Koji Tanaka; Yasuhiro Inoue; Yuji Toiyama; Yoshinaga Okugawa; Takashi Iwata; Yasuhiko Mohri; Masato Kusunoki
Journal:  Int Surg       Date:  2014 May-Jun

7.  Research and clinical applications of molecular biomarkers in gastrointestinal carcinoma (Review).

Authors:  Feng Jiao; Ziliang Jin; Lei Wang; Liwei Wang
Journal:  Biomed Rep       Date:  2013-08-20

8.  Associations between polymorphisms in the IL-4 and IL-4 receptor genes and urinary carcinomas: a meta-analysis.

Authors:  Yun Luo; Zhiqiang Ye; Ke Li; Ruihan Chen; Shigeng Li; Jun Pang
Journal:  Int J Clin Exp Med       Date:  2015-01-15

9.  Association between polymorphism of the interleukin-13 gene and susceptibility to hepatocellular carcinoma in the Chinese population.

Authors:  Yan Deng; Ming Xie; Li Xie; Jian Wang; Taijie Li; Yu He; Ruolin Li; Shan Li; Xue Qin
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

10.  Reduced type II interleukin-4 receptor signalling drives initiation, but not progression, of colorectal carcinogenesis: evidence from transgenic mouse models and human case-control epidemiological observations.

Authors:  Nicola Ingram; Emma L Northwood; Sarah L Perry; Gemma Marston; Helen Snowden; John C Taylor; Nigel Scott; D Timothy Bishop; P Louise Coletta; Mark A Hull
Journal:  Carcinogenesis       Date:  2013-06-19       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.